IMMUNOVIA AB overview

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...

Immunovia discovery study published in top protein research journal PR Newswire LUND, Sweden, Dec. 20, 2024 LUND, Sweden , Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research . The study is the largest and most comprehensive pancreatic...

End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding PR Newswire LUND, Sweden, Dec. 19, 2024 LUND, Sweden , Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025. In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success As 2024 began, we had recently completed a significant transformation of the company. We were a much smaller, more...

Immunovia CEO and board members announce intention to fully exercise their TO2 warrants PR Newswire LUND, Sweden, Dec. 18, 2024 LUND, Sweden , Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024 . Immunovia CEO Jeff Borcherding , one of the company's largest shareholders based on...

Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, Dec. 16, 2024 LUND, Sweden , Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024 . As a follow up, Immunovia will host a webcast on Tuesday,...

Immunovia announces financial calendar for financial year 2025/2026 PR Newswire LUND, Sweden, Dec. 11, 2024 LUND, Sweden , Dec. 11, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026. Year-End 2024 Report February 25 , 2025 Q1 Report, 2025 May 14 , 2025 Q2 Report, 2025 August 21 , 2025 Q3 Report, 2025 November 19, 2025 Year-End 2025 Report...

Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer PR Newswire LUND, Sweden, Dec. 9, 2024 LUND, Sweden , Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC). In the...